Latest Pharmaceutical and Healthcare disease pipeline guide Amyloidosis Pipeline Review, H2 2017, provides an overview of the Amyloidosis (Metabolic Disorders) pipeline landscape.
Amyloidosis Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Amyloidosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Purchase This Single User License PDF Report of 157 pages at: http://www.reportsnreports.com/purchase.aspx?name=1132644
The Amyloidosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Amyloidosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 4, 7, 7, 6 and 4 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 3 molecules, respectively.
Amyloidosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Discount is available on Amyloidosis report at http://www.reportsnreports.com/contacts/discount.aspx?name=1132644
Companies are Alnylam Pharmaceuticals Inc, Amgen Inc , Arcturus Therapeutics Inc, Bsim2 , Celgene Corp, GlaxoSmithKline Plc, Ionis Pharmaceuticals Inc, Johnson & Johnson, Millennium Pharmaceuticals Inc, Neurimmune Holding AG, Novartis AG, Oncopeptides AB, Pfizer Inc , Prothena Corp Plc, R Pharm , Regeneron Pharmaceuticals Inc , SOM Biotech SL , Spectrum Pharmaceuticals Inc
List of Figures
Number of Products under Development for Amyloidosis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
ReportsandReports.com is your single source for all market research needs. Our database includes 100,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
2nd Floor, Metropole,
Bund Garden Road,
Pune – 411001,
Tel: + 1 888 391 5441